{"contentid": 488716, "importid": NaN, "name": "Roche\u00e2\u0080\u0099s COVID-19 antibody cocktail now available in India, marketed by Cipla", "introduction": "The Indian subsidiary of Swiss pharma major Roche and domestic drugmaker Cipla Limited today announced that the first batch of the Roche antibody cocktail (casirivimab and imdevimab) is now available in India, while a second batch will be made available by mid-June.", "content": "<p>The Indian subsidiary of Swiss pharma major Roche (ROG: SIX) and domestic drugmaker Cipla Limited (BSE: 500087) today announced that the first batch of the Roche antibody cocktail (casirivimab and imdevimab) is now available in India, while a second batch will be made available by mid-June.</p>\n<p>In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients, said Cipla. Financial aspects of the collaboration are not disclosed.</p>\n<p>Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID-19 treatment centers. The Central Drugs Standards Control Organization (CDSCO) had recently provided an Emergency Use Authorization (EUA) for the antibody cocktail in India. It has also received a EUA in the USA and several EU countries.</p>\n<h2><strong>Treatment cost</strong></h2>\n<p>In India, the product is priced at 59,750 rupees ($820) per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk. In the USA, the antibody cocktail, that was developed by Regeneron Pharmaceutical (Nasdaq: REGN), is estimated to cost somewhere between $1,500 and $6,500 per treatment. Regeneron posted $262 million in first-quarter sales of the therapy.</p>\n<p>In January this year, the US Department of Health and Human Services (HHS) and the Department of Defense (DoD) said they will purchase up to 1.25 million additional doses of the casirivimab and imdevimab antibody cocktail for use in non-hospitalized COVID-19 patients to meet the federal government's Operation Warp Speed goals. The agreement has a value of up to $2.625 billion.</p>\n<p>&ldquo;Roche is deeply committed to support the ongoing efforts to combat the COVID-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimizing hospitalization, ease the burden on healthcare systems and play a key role in treatment of high risk patients before their condition worsens,&rdquo; said V Simpson Emmanuel, managing director and chief executive of Roche Pharma India. &nbsp;</p>\n<p>Also commenting on the launch, Cipla MD and CEO Umang Vohra, said: &ldquo;We are guided by our strong sense of responsibility to address unmet patient need and look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country&rdquo;.</p>\n<p>The antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age or older, weighing at least 40kg) who are confirmed to be infected with SARS-COV2 and who are at high risk* of developing severe COVID-19 disease and do not require oxygen. It has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalization and fatality by 70% and shortening the duration of symptoms by four days.</p>", "date": "2021-05-24 12:29:00", "meta_title": "Roche\u00e2\u0080\u0099s COVID-19 antibody cocktail now available in India, marketed by", "meta_keywords": "Roche, Cipla, Launch, Antibody cocktail, Casirivimab and imdevimab, COVID-19", "meta_description": "Roche\u00e2\u0080\u0099s COVID-19 antibody cocktail now available in India, marketed by Cipla", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-24 12:28:23", "updated": "2021-05-24 12:35:42", "access": NaN, "url": "https://www.thepharmaletter.com/article/roche-s-covid-19-antibody-cocktail-now-available-in-india-marketed-by-cipla", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "cipla-big.png", "image2id": "cipla-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases", "topic_tag": "Coronavirus, Deals, Focus On, Product Launch", "geography_tag": "Ankleshwa, Gujarat, India, India, Switzerland, USA", "company_tag": "Cipla, Regeneron Pharmaceuticals, Roche", "drug_tag": "casirivimab, imdevimab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-24 12:29:00"}